Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Buy" by Analysts : vimarsana.com

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]

Related Keywords

Mark Mcdade , Jefferies Financial Group , Nasdaq , Capital Management , Denali Advisors , Affinity Asset Advisors , Tourmaline Bio Inc , Jump Financial , Tourmaline Bio , Get Free Report , Financial Group , Truist Financial , Director Mark Mcdade , Asset Advisors , Get Free , Tourmaline Bio Daily , Nasdaq Trml , Trml , Medical , Ratings , Consensus ,